C-WRZLOrigami Therapeutics
protein degradation, small molecules, neurodegeneration
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-WRZL
C-WRZLC-WRZLprotein degradation, small molecules, neurodegeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Origami Therapeutics protein degradation, small molecules, neurodegeneration
Origami Therapeutics is developing next-generation disease-modifying protein degraders and correctors. Its therapies target and degrade disease-related proteins while sparing normal forms of the protein. The company focuses on neurodegenerative diseases including Alzheimer's, Huntington's, Parkinson's, amyotrophic lateral sclerosis, and frontotemporal dementia.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Origami Therapeutics — Far from goals · Bottom quartile. Derived deterministically from 6 extracted project(s). Most-advanced status: undisclosed. Band: far. Modifiers: +5 depth (6 programs at undisclosed).…
Source: Deterministic